Chimeric Therapeutics Reports Promising Results in ADVENT-AML Trial

Chimeric Therapeutics Ltd. ( (AU:CHM) ) just unveiled an announcement.

Chimeric Therapeutics has announced promising results from its ADVENT-AML Phase 1B clinical trial, which combines standard AML treatment with its CORE-NK technology. The trial, conducted at MD Anderson Cancer Center, has shown that two out of three patients achieved complete response with incomplete blood count recovery, indicating potential transformative treatment for AML patients not eligible for chemotherapy or stem cell transplant. The trial’s success could position Chimeric as a pioneer in cell therapy for AML, potentially benefiting newly diagnosed patients and enhancing the company’s standing in the cell therapy sector.

More about Chimeric Therapeutics Ltd.

Chimeric Therapeutics is a clinical-stage cell therapy company focused on developing innovative cell therapies for cancer treatment. The company is engaged in the discovery, development, and commercialization of promising cell therapies, with a diverse portfolio that includes CAR-T and allogeneic NK cell therapies across multiple oncology areas.

Technical Sentiment Signal: Sell

Current Market Cap: A$8.33M

Find detailed analytics on CHM stock on TipRanks’ Stock Analysis page.